摘要:
The present invention relates generally to a novel method of introducing property modifying groups to a protein. In particular, the present invention relates to the derivatization of lysine residues, as well as new conjugates of growth hormones with improved pharmacological properties, and methods for their preparation and use in therapy.
摘要:
Novel growth hormone conjugates comprising a growth hormone compound (GH) and a growth hormone binding protein (GHBP) are disclosed. The invention also encompasses a novel derivatization method for producing stable, long-lasting conjugate (hGH-GHBP) by site specific conjugation. The novel GH-GHBP conjugates have an extended half-life in circulation that facilitates therapeutic use of the protein. The GH-GHBP conjugates exhibit pharmacological properties such as increased functional in vivo half-life, improved renal filtration, improved protease protection and albumin binding.
摘要:
The present invention relates to a method of treating migraine, non-insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation and/or vasomotor disturbances. This method utilizes a hexapeptide of formula (I)A.sup.1 -A.sup.2 -A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -Y (I)wherein A.sup.1, A.sup.2, A.sup.3, A.sup.4, A.sup.5, A.sup.6 and Y are as defined in the specification.
摘要:
Novel peptide derivatives, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed. These peptide derivatives have the formula: A--B--C--D--E (--F).sub.p wherein A, B, C, D, E, F and p are as defined in the specification. These peptides exhibit improved resistance to proteolytic degradation as well as improved growth hormone releasing activity.
摘要:
The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
摘要:
Variants of transglutaminase from S. mobareanse, which variants have improved selectivity against Gln-40 og Gln-141 of human growth hormone are provided.